Antiarrhythmic drugs Flashcards

1
Q

Procainamide MOA

A

Class 1a

  • Na+ channel blocker=primary
  • K+ channel blocker=secondary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Procainamide effects

A

Slows conduction velocity and pacemaker rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Procainamide clinical applications

A

Atrial and ventricular arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Procainamide side effects

A
  1. Torsades de pointes in pt’s with renal failure
  2. Hypotension
  3. Long term: Reversible lupus-related sx’s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lidocaine MOA

A

Class 1b

  • Weak Na+ channel blocker
  • Minimal effect on normal tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lidocaine Clinical applications

A

Ventricular arrhythmias (post-MI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lidocaine toxicity

A

Neurologic sx’s: CNS sedation or excitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Who do we want to reduce Lidocaine dose in?

A
  1. HF pt’s

2. Liver dz pt’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Flecainide MOA

A

Group 1c

-Strong Na+ channel blocker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Flecainide effects

A

No change in AP duration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Flecainide Clinical application

A

Treat supra ventricular arrhythmias (SVT) in pt’s with a NORMAL HEART

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Who do we want to avoid giving Flecainide to?

A

Ischemic heart disease pt’s (post-MI)

Pro-arrhythmic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Class II drugs

A

Beta-Blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Beta-Blockers effects

A

Prolongation of AP duration

  1. Slows SA node automaticity
  2. Slows AV nodal conduction velocity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Beta-Blocker Clinical applications

A
  1. Atrial arrhythmias

2. Prevention of recurrent infarction an sudden death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Beta-Blocker toxicity

A
  1. Asthma
  2. AV block
  3. Acute HF
17
Q

Class III drug

A
  1. Amiodarone

2. Dofetilide

18
Q

Amiodarone MOA

A

Blocks K+ channels

19
Q

Amiodarone effects

A
  1. Prolongs QT (repolarization)

2. Prolongs AP= Prolongs effective refractory period!!!

20
Q

Amiodarone clinical applications

A
  1. Serious Ventricular arrhythmias

2. SVT

21
Q

Amiodarone toxicity

A
  1. Thyroid dysfunction: Hyper-hypothyroidsim
  2. Pulmonary fibrosis
  3. Optic neuritis
22
Q

Amiodarone drug interaction

A

Many, based on CYP metabolism

23
Q

What is considered the blue/ash man drug? Why? How do you protect against this?

A
  1. Drug: Amiodarone
  2. Photosensitivity: blue/gray skin
  3. WEAR SUNBLOCK
24
Q

What drug has to be initiated in the hospital? Why?

A

Dofetilide

–>Torsades de point toxicity

25
Class IV drugs
Calcium channel blockers: 1. Verapamil 2. Diltiazem
26
Effects of CCB
1. Slows AV node conduction | 2. Slows SA node
27
Verapamil clinical application
1. AV nodal arrhythmias-especially in prophylaxis
28
Diltiazem clinical applications
Rate control in a-fib
29
CCB side effects
1. Constipation | 2. Hypotension
30
Magnesium clinical application
1. Torsades de pointes | 2. Digitalis induced arrhythmias
31
Magnesium toxicity
Muscle weakness with overdose
32
What does Magnesium oppose?
Calcium
33
What ion is critical to functionality of Ca2+ channels and Na+/K+ ATPase pump?
Magnesium
34
Potassium toxicity?
1. Reentrant arrhythmia | 2. Fibrillation or arrest in overdose
35
Adenosine MOA
Increases K+ efflux of SA and AV node= hypwrpolarazing cell and decreasing frequency of cellular activation
36
Adenosine clinical application
Paroxysmal SVT
37
Adenosine toxicities
1. Flushing 2. Chest tightness-"heart will stop" 3. Dizziness/Hypotension 4. Dyspnea